• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    (OP:ONNVF)

    0.7000 UNCHANGED
    Streaming Delayed Price Updated: 2:57 PM EDT, May 18, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about ONNVF

    < Previous 1 2 Next >
    News headline image
    Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
    Via ACCESS Newswire
    News headline image
    OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI
    From OneMedNet Corporation
    Via GlobeNewswire
    News headline image
    Onco-Innovations Announces Closing of Private Placement
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Announces Amendment to Private Placement Pricing
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Attends University of Alberta's 2025 Innovation Awards
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development
    Via ACCESS Newswire
    News headline image
    Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Appoints Jared Rushton to Board of Directors
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Announces Closing of Private Placement
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Announces Private Placement
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Advances Preclinical Program as Nucro-Technics Begins Analytical Development for PNKP Technology
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board
    Via ACCESS Newswire
    News headline image
    Onco-Innovations Commences Activities to Manufacture Nanoparticle Formulation with Dalton Pharma to Supply Preclinical Animal Studies
    Via ACCESS Newswire
    News headline image
    Onco-Innovations to Chair Colorectal Cancer Canada Precision Oncology Forum Driving the Future of Cancer Care
    Via ACCESS Newswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.